Publications by authors named "Samuel Malkin"

Claim this Profile
O
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Samuel J P Malkin

Cardiovasc Diabetol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Drug-Coated Balloons in the Treatment of Coronary Small Vessel Disease: A Report From the BASKET-SMALL 2 Randomized Controlled Trial.
Marco E G V Cattaneo, Michael Coslovsky, Samuel J P Malkin, Gregor Fahrni, Christoph Kaiser

J Am Heart Assoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
Mohamed Elnaggar, Joana Nunes Mansinho, Samuel J P Malkin, Joseph Whitaker, Barnaby Hunt

Diabetes Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia.
Mohammed Alluhidan, Abdulrahman Alturaiki, Hana Alabdulkarim, Nasser Aljehani, Essam A Alghamdi, Samuel J P Malkin

Adv Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes.
Ting Zhao, Michelle Tew, Talitha Feenstra, Pieter van Baal, Michael Willis, Samuel J P Malkin

Appl Health Econ Health Policy· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India.
Jack Garcia Uranga Romano, Samuel Joseph Paul Malkin, Barnaby Hunt

Value Health Reg Issues· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
Sasha Berry, Barrie Chubb, Annabel Acs, Edel Falla, Akanksha Verma, Samuel J P Malkin

J Med Econ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Hongye Ren, Sasha Berry, Samuel Joseph Paul Malkin, Barnaby Hunt, Stephen Bain

BMJ Open· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Adie Viljoen, Barrie Chubb, Samuel J P Malkin, Sasha Berry, Barnaby Hunt

Eur J Health Econ· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
Marc Evans, Sasha Berry, Samuel J P Malkin, Barnaby Hunt, Abheet Sharma

Diabetes Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
Marc Evans, Sasha Berry, Avideh Nazeri, Samuel Jp Malkin, Donna Ashley

Diabetes Obes Metab· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Marc Evans, Barrie Chubb, Samuel J P Malkin, Sasha Berry, Jack Lawson

Diabetes Obes Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands.
Robert Gerald Jan Moes, Eline L Huisman, Samuel J P Malkin, Barnaby Hunt

Clinicoecon Outcomes Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Josep Franch-Nadal, Samuel J P Malkin, Barnaby Hunt, Virginia Martín, María Gallego Estébanez

Adv Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Samuel J P Malkin, Davide Carvalho, Catarina Costa, Vasco Conde, Barnaby Hunt

Diabetol Metab Syndr· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
Margareta Hellgren, Ann-Marie Svensson, Stefan Franzén, Åsa Ericsson, Soffia Gudbjörnsdottir, Samuel Malkin

Diabetes Obes Metab· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Samuel J P Malkin, Barnaby Hunt, Eline L Huisman, Tobias S Grand, Barrie Chubb

Diabetes Res Clin Pract· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, Samuel J P Malkin

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Virginia Martín, Josep Vidal, Samuel J P Malkin, Nino Hallén, Barnaby Hunt

Adv Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J P Malkin, Anna Sandberg

Adv Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Barnaby Hunt, Samuel J P Malkin, Robert G J Moes, Eline L Huisman, Tom Vandebrouck

BMJ Open Diabetes Res Care· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Anthony J Cannon, Alexandra Bargiota, Liana Billings, Barnaby Hunt, Lawrence A Leiter, Samuel Malkin

J Manag Care Spec Pharm· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Josep Vidal, Samuel J P Malkin, Barnaby Hunt, Virginia Martín, Nino Hallén

Diabetes Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Stephen C Bain, Brian B Hansen, Samuel J P Malkin, Solomon Nuhoho, William J Valentine

Diabetes Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Barnaby Hunt, Brian B Hansen, Åsa Ericsson, Klaus Kallenbach, Sarah N Ali, Samuel J P Malkin

Adv Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis